Evaluation of the Hepatocellular Carcinoma Predictive Scores PAGE-B and mPAGE-B among Brazilian Patients with Chronic Hepatitis B Virus Infection

Imagem de Miniatura
Arquivos
art_SILVA_Evaluation_of_the_Hepatocellular_Carcinoma_Predictive_Scores_PAGEB_2022.PDF (1.8 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
SILVA, Ana Caroline Ferreira da
CUNHA-SILVA, Marlone
SEVA-PEREIRA, Tiago
Citação
VIRUSES-BASEL, v.14, n.9, article ID 1968, 14p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hepatitis B virus (HBV) is intrinsically oncogenic and related to hepatocellular carcinoma (HCC). Predictive scores of HCC have been developed but have been poorly studied in admixed populations. Therefore, we aimed to evaluate the performance of PAGE-B and mPAGE-B scores for HCC prediction in HBV Brazilian patients and factors related to HCC occurrence. This is a retrospective study that evaluated patients followed at a tertiary university center. A total of 224 patients were included, with a median follow-up period of 9 years. The mean age at HBV diagnosis was 38.71 +/- 14.19 years, predominantly males (66.1%). The cumulative incidence of HCC at 3, 5, and 7 years was 0.993%, 2.70%, and 5.25%, respectively, being related in the univariate logistic regression analysis to male sex (p = 0.0461), older age (p = 0.0001), cirrhosis at HBV diagnosis (p < 0.0001), and higher values of PAGE-B and mPAGE-B scores (p = 0.0002 and p < 0.0001, respectively). Older age, male sex, and cirrhosis at HBV diagnosis were independently associated with HCC occurrence. The AUROCs of PAGE-B and mPAGE-B were 0.7906 and 0.7904, respectively, with no differences between them (p = 0.9767). In conclusion, both PAGE-B and mPAGE-B showed a correct prediction of HCC above 70% in this cohort.
Palavras-chave
hepatitis B virus, hepatocellular carcinoma, risk factors
URI
https://observatorio.fm.usp.br/handle/OPI/49514
Referências
  1. Akbulut S, 2022, J GASTROINTEST CANC, DOI 10.1007/s12029-022-00830-2
  2. Alvarado-Mora MV, 2013, ANTIVIR THER, V18, P429, DOI 10.3851/IMP2595
  3. BEASLEY RP, 1982, HEPATOLOGY, V2, P553
  4. Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
  5. CHAGAS Aline Lopes, 2020, Arq. Gastroenterol., V57, P1, DOI [10.1590/S0004-2803.202000000-20, 10.1590/s0004-2803.202000000-20]
  6. Chen YX, 2018, ONCOTARGETS THER, V11, P6277, DOI 10.2147/OTT.S154848
  7. Choe JW, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112401
  8. Cunha-Silva M, 2017, BRAZ J INFECT DIS, V21, P441, DOI 10.1016/j.bjid.2017.03.019
  9. Costa APD, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14040732
  10. European Assoc Study Liver, 2018, J HEPATOL, V69, P154, DOI 10.1016/j.jhep.2018.03.018
  11. European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  12. Fan R, 2020, J HEPATOL, V73, P1368, DOI 10.1016/j.jhep.2020.07.025
  13. Geh D, 2022, BMJ OPEN GASTROENTER, V9, DOI 10.1136/bmjgast-2021-000794
  14. Ghany MG, 2020, LANCET GASTROENTEROL, V5, P406, DOI 10.1016/S2468-1253(19)30344-9
  15. Goldberg DS, 2017, HEPATOLOGY, V65, P864, DOI 10.1002/hep.28765
  16. Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086
  17. Huang ZH, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09413-7
  18. Jang H, 2022, CLIN GASTROENTEROL H, V20, P1343, DOI 10.1016/j.cgh.2021.09.001
  19. Kim JH, 2018, J HEPATOL, V69, P1066, DOI [10.1016/s0168-8278(18)31215-7, 10.1016/j.jhep.2018.07.018]
  20. Kirino S, 2020, J GASTROEN HEPATOL, V35, P1595, DOI 10.1111/jgh.14990
  21. Lam L, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2021.101713
  22. Lee YB, 2021, HEPATOLOGY, V73, P2266, DOI 10.1002/hep.31612
  23. Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021
  24. Liang TJ, 2009, HEPATOLOGY, V49, pS13, DOI 10.1002/hep.22881
  25. Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3
  26. Ministerio da Saude Boletim, 2021, EP HEP VIR
  27. Papatheodoridis G, 2016, J HEPATOL, V64, P800, DOI 10.1016/j.jhep.2015.11.035
  28. Papatheodoridis GV, 2015, J HEPATOL, V62, P956, DOI 10.1016/j.jhep.2015.01.002
  29. Raffetti E, 2016, LIVER INT, V36, P1239, DOI 10.1111/liv.13142
  30. Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4
  31. Sharma SA, 2018, J HEPATOL, V68, P92, DOI 10.1016/j.jhep.2017.07.033
  32. Simonovsky V, 1999, BRIT J RADIOL, V72, P29, DOI 10.1259/bjr.72.853.10341686
  33. Sprinzl MF, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-06794-6
  34. Tan YF, 2019, CANCER EPIDEM BIOMAR, V28, P2038, DOI 10.1158/1055-9965.EPI-19-0303
  35. Tseng CH, 2020, J GASTROEN HEPATOL, V35, P1684, DOI 10.1111/jgh.15078
  36. Vallet-Pichard A, 2021, ALIMENT PHARM THER, V53, P1166, DOI 10.1111/apt.16356
  37. Voulgaris T, 2020, LIVER INT, V40, P484, DOI 10.1111/liv.14334
  38. Wong VWS, 2010, J CLIN ONCOL, V28, P1660, DOI 10.1200/JCO.2009.26.2675
  39. World Health Organization, HEP B
  40. World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
  41. Wu SS, 2021, CLIN GASTROENTEROL H, V19, P2499, DOI 10.1016/j.cgh.2021.02.040
  42. Yang HI, 2011, LANCET ONCOL, V12, P568, DOI 10.1016/S1470-2045(11)70077-8
  43. Yang LQ, 2021, CAN J GASTROENTEROL, V2021, DOI 10.1155/2021/9996358
  44. Yip TCF, 2020, J HEPATOL, V72, P847, DOI 10.1016/j.jhep.2019.12.005
  45. Yuen MF, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2018.35, 10.1038/nrdp.2018.36]
  46. Yuen MF, 2009, J HEPATOL, V50, P80, DOI 10.1016/j.jhep.2008.07.023

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03